|
Post by JHam on Oct 21, 2014 11:58:48 GMT
Here is a new stock that I am very interested in and opened a position in yesterday. Brief rundown: - $67M in cash - 10.20M shares outstanding - $48M market cap - Listed on the OTC with a $4.75 share price - Focused on topical and immunotherapy drugs NRIFF sold their U.S. rights to Pennsaid 2% for $45M. After receiving $10M from the lawsuit settlement with MNK, NRIFF now has $67M in cash. With a $48M market cap they have more cash per share than price per share. Very low burn rate at about $2.5M a quarter and a major catalyst upcoming with the release of final Phase 2 data for their WF10 trial in Q1 2015. WF10 is for the treatment of allergic rhinitis and has showed far superior results compared to the current forms of treatment. Allergenic rhinitis represents a $10B market in the US alone, and that is a very conservative in my opinion. Important links: www.nuvoresearch.com/www.nuvoresearch.com/documents/presentations/2014-10-08_Nuvo_IR_Presentation_October_2014.pdf
|
|
|
Post by JHam on Oct 21, 2014 12:13:00 GMT
|
|
|
Post by JHam on Oct 21, 2014 12:14:34 GMT
Not very common to find a company who has more cash per share than price per share. As long as they can keep revenue around the current annual number of $19M their cash position shouldn't really change from the current $67M...unless it grows. It will take a hit since they won't be getting revenue from sales of Pennsaid anymore, but it looks as though they are going to continue to receive royalties. According to Jason N, they are going to try and get more active outside the US with Pennsaid so I feel confident revenue can still outpace the burn rate.
|
|
|
Post by JHam on Oct 22, 2014 17:39:51 GMT
News out. Market study results for WF10. Highlighted parts are mine: www.prnewswire.com/news-releases/nuvo-research-completes-wf10-us-market-study-for-treatment-of-refractory-allergies-280027142.htmlNuvo Research® Completes WF10™ U.S. Market Study for Treatment of Refractory Allergies MISSISSAUGA, ON, Oct. 22, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced the results of a market study commissioned to investigate the U.S. opportunity for the Company's experimental immunotherapy product, WF10, as a treatment for patients with refractory allergic rhinitis. The study, performed by Psscion Lifesciences Consulting (Psscion), forecasts that WF10 could capture 10-15% of the U.S. refractory allergic rhinitis market with peak U.S. annual sales of US$0.7 billion to US$1.1 billion. "This market study confirms the significant U.S. market opportunity for WF10 to treat refractory allergic rhinitis," said Dr. Henrich Guntermann, President of Nuvo's Europe & Immunology Group. "Our clinical and case study data suggests that WF10 is a revolutionary therapy that provides symptomatic relief from multiple airborne allergens for up to 2 years after only 5 days of treatment. We are eagerly awaiting results in Q1 2015 of our ongoing 183 patient Phase 2 allergic rhinitis clinical study that is designed to confirm the positive results achieved in our earlier 60 patient Phase 2 proof-of-concept study." About The Psscion StudyThe market study was conducted by Psscion, a U.S. based firm that provides strategic advice and market research to the pharmaceutical industry. Psscion was retained to assist Nuvo in determining the optimum strategy to maximize the value of WF10 for the treatment of refractory allergic rhinitis. In the course of the study, Psscion interviewed patients with refractory allergic rhinitis, practicing physicians specializing as allergists and immunologists and representatives from insurance companies and other payers. The additional findings in the study were: Physicians were impressed by WF10's efficacy, long-lasting therapeutic effect, ability to treat multiple allergens with one dosing regimen and favourable safety profile as observed in the Company's completed 60 patient Phase 2 proof-of-concept study and case studies; Patients and physicians believe that WF10 would address an unmet need in the treatment of refractory allergic rhinitis; WF10 could be an attractive alternative to subcutaneous immunotherapy (SCIT) also known as "allergy shots" which are allergen specific and can continue for months or years causing many patients to either refuse or discontinue SCIT treatment; and Payers rated WF10 positively and felt that WF10 was unlikely to face significant barriers to coverage.About the Company's Ongoing WF10 Phase 2 Clinical Trial This 16 week clinical trial is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of a regimen of five infusions of either WF10 or its main constituents (sodium chlorite and sodium chlorate) relative to saline control in allergic rhinitis patients experiencing persistence or recurrence of symptomatic episodes in spite of conventional treatment over the previous year. The trial will measure total nasal symptom score (TNSS) and other secondary endpoints. The trial is being conducted at 15 sites in Germany. It is fully enrolled with 183 patients participating. Top-line results are expected in Q1 2015. The trial is designed to confirm the results of the Company's 2010 60 patient, randomized, double-blind, placebo-controlled, single-center Phase 2 clinical study of WF10 for the treatment of allergic rhinitis which achieved statistical significance (P<0.001) for its primary endpoint (change in TNSS at week 3). About Refractory Allergic RhinitisAllergic rhinitis, a highly prevalent condition characterized by nasal symptoms (runny, blocked, or itchy nose; chronic sneezing) is triggered by an inappropriate immune response to one or more allergens such as pollens, house dust mites and pet dander. Refractory allergic rhinitis patients often suffer from severe symptoms and do not respond adequately to common forms of treatment such as antihistamines and nasal corticosteroids. Most refractory allergic rhinitis patients suffer from multiple allergies. About WF10 WF10 is a solution containing stabilized chlorite ions that focuses on supporting the immune system by targeting the macrophage, a type of white blood cell that coordinates much of the immune system, to regulate normal immune function. WF10 is an infusion therapy currently approved only in Thailand under the name IMMUNOKINE for the treatment of post-radiation-therapy syndrome. About Nuvo Research Inc.Nuvo (TSX:NRI) is a specialty pharmaceutical company with a diverse portfolio of products and technologies. The Company operates two distinct business units: the Topical Products and Technology (TPT) Group and the Immunology Group. The TPT Group has four U.S. Food and Drug Administration (FDA) approved commercial products, a pipeline of topical and transdermal products focusing on pain and dermatology and four drug delivery platforms that support the development of patented formulations that can deliver actives into or through the skin. The Immunology Group has two commercial products, a development program for the treatment of allergic rhinitis and an immune system modulation platform that has the potential to support treatments for a broad range of immune system related disorders. For additional company information visit www.nuvoresearch.com. About Psscion Lifesciences ConsultingPsscion specializes in consulting services for the lifesciences sector. Our people, approach and perspectives enable us to provide exceptional results for client companies. Psscion delivers marketing, commercialization strategy and corporate development services that maximize R&D effectiveness, build differentiated product value and achieve sustained market advantage for pharmaceutical, biotech and medical technology companies. Psscion partners with leading experts in a range of fields including data analytics, health outcomes, reimbursement and access, public relations and medical writing. For additional information visit www.psscion.com.
|
|
|
Post by RLC on Nov 1, 2014 2:38:24 GMT
Thanks for posting all of this JHam. I recently opened a very small position at $4.60. This company does seem like a diamond in the rough (lots of cash, low burn rate, increasing revenues, positive SE, etc.). The chart doesn't look too bad either. My only beef is the low volume, but hopefully that changes soon. I'm going to try to start keeping up with this one and might look to add to my position if it drops much lower from here.
|
|
|
Post by JHam on Nov 1, 2014 4:57:52 GMT
Thanks for posting all of this JHam. I recently opened a very small position at $4.60. This company does seem like a diamond in the rough (lots of cash, low burn rate, increasing revenues, positive SE, etc.). The chart doesn't look too bad either. My only beef is the low volume, but hopefully that changes soon. I'm going to try to start keeping up with this one and might look to add to my position if it drops much lower from here. The volume is almost non-existent which is a head scratcher. I've been doing as much digging as possible to find reasons why this one is still so under the radar (besides the fact that it is on the pink sheets). So far I haven't found anything and am wondering (hoping) that this is one of those cases where it will just take off once people become aware of it. I am averaged at $4.77 with a fairly small position, but will look to increase it as we get closer to Q1. I may even try and pick some up on Monday thanks to the nice drop today.
|
|
|
Post by JHam on Nov 1, 2014 5:06:43 GMT
$1B in annual sales for WF10 (based on the market study) would give the company over a $100 share price if you were to throw that into the market cap. As I said in a different post, with $67 in cash and annual revenues that outpace their annual burn rate, there is no need for them to dilute. Unless they feel like they need to have more o/s available.
I also think that $.7-1.1B number for annual WF10 sales is a bit conservative when you see how the company formulated their figures in their presentation slides.
|
|
|
Post by RLC on Nov 3, 2014 17:51:15 GMT
Added a little more today. It's hilarious that my purchase has made up ~85% of today's volume.
|
|
|
Post by JHam on Nov 3, 2014 17:58:38 GMT
Added a little more today. It's hilarious that my purchase has made up ~85% of today's volume. Hilarious and a little frightening Hopefully the volume will start to change as we get closer to Q1.
|
|
|
Post by RLC on Nov 3, 2014 19:02:58 GMT
Added a little more today. It's hilarious that my purchase has made up ~85% of today's volume. Hilarious and a little frightening Hopefully the volume will start to change as we get closer to Q1. For whatever reason... I'm not too concerned. I like the fact that there's plenty of untouched territories for Pennsaid (and Pennsaid 2%). Hopefully they can partner the selling rights out to other companies in these areas just as they did with Horizon in the US. I think their PR announced today backs their plan to do this. And the market study that was recently completed for WF10 is very exciting. I'm really looking forward to the results of the Phase 2 allergic rhinitis study (expected in Q1 2015)!
|
|
|
Post by RLC on Nov 11, 2014 4:18:08 GMT
Go NUVO!!! This little guy has been my biggest % gainer over the last couple of weeks. There's a whole lot to like about this company at ~$5/share...
|
|
|
Post by JHam on Nov 11, 2014 10:05:33 GMT
Go NUVO!!! This little guy has been my biggest % gainer over the last couple of weeks. There's a whole lot to like about this company at ~$5/share... Yeah I can't complain either. I am comfortably in the green with this one and like always just wish I would have bought more in the $4's. It's still way undervalued at these levels though so I plan on buying more soon.
|
|
|
Post by JHam on Nov 13, 2014 15:04:47 GMT
Nice uptick the past few days followed by a small pop today. Currently up 22%, but am definitely holding onto this one and likely adding as I feel this has still yet to show up on most people's radar.
|
|
|
Post by lcd on Nov 13, 2014 15:24:43 GMT
I tried to buy some of this stock last week at the ask ($4.50) but couldn't find a seller. The number of shares moving is so low that I wonder if they even have a market maker. It has jumped significantly, but if you own even a few hundred shares I doubt you will be able to sell them all. I will sit on the sidelines and watch this one. Good luck.
|
|
|
Post by JHam on Nov 13, 2014 15:33:20 GMT
I tried to buy some of this stock last week at the ask ($4.50) but couldn't find a seller. The number of shares moving is so low that I wonder if they even have a market maker. It has jumped significantly, but if you own even a few hundred shares I doubt you will be able to sell them all. I will sit on the sidelines and watch this one. Good luck. That's a good point. There is definitely not much liquidity with this one. I guess I'll have to cross that bridge when I get to it. Hopefully that will start to change as we approach Q1-15.
|
|
|
Post by RLC on Nov 13, 2014 15:53:12 GMT
I tried to buy some of this stock last week at the ask ($4.50) but couldn't find a seller. The number of shares moving is so low that I wonder if they even have a market maker. It has jumped significantly, but if you own even a few hundred shares I doubt you will be able to sell them all. I will sit on the sidelines and watch this one. Good luck. I had to bump my buy price up significantly above the last trade to get my order in. I think selling would work the same way (you'll have to ask for less than last trade). I do, however, feel that this stock will continue to trend towards a fairer valuation (seems greatly undervalued) and when they release some big news, there will be plenty of volume to unload if one chooses to do so. At least this is my hope! I'm up almost 30% on this one!
|
|
|
Post by JHam on Nov 13, 2014 15:58:23 GMT
I tried to buy some of this stock last week at the ask ($4.50) but couldn't find a seller. The number of shares moving is so low that I wonder if they even have a market maker. It has jumped significantly, but if you own even a few hundred shares I doubt you will be able to sell them all. I will sit on the sidelines and watch this one. Good luck. I had to bump my buy price up significantly above the last trade to get my order in. I think selling would work the same way (you'll have to ask for less than last trade). I do, however, feel that this stock will continue to trend towards a fairer valuation (seems greatly undervalued) and when they release some big news, there will be plenty of volume to unload if one chooses to do so. At least this is my hope! I'm up almost 30% on this one! Wow that's great RLC! I think you get the bargain basement buy trophy Seriously though, up 30% with the main catalyst still at least 2 months out bodes well in my opinion.
|
|
|
Post by RLC on Nov 13, 2014 16:17:03 GMT
I had to bump my buy price up significantly above the last trade to get my order in. I think selling would work the same way (you'll have to ask for less than last trade). I do, however, feel that this stock will continue to trend towards a fairer valuation (seems greatly undervalued) and when they release some big news, there will be plenty of volume to unload if one chooses to do so. At least this is my hope! I'm up almost 30% on this one! Wow that's great RLC! I think you get the bargain basement buy trophy Seriously though, up 30% with the main catalyst still at least 2 months out bodes well in my opinion. Ya I got lucky with my purchase price. I think you had mentioned you opened a small position ~$4.70. Shortly after, I did a little digging into the company, liked what I saw and decided to buy. It was trading at ~$4.50 I believe and I got my first purchase in at $4.60. A few days later, it continued trading down slightly, and I managed to grab a larger chunk at $4.45. Between this one and ONCS, I'd say I owe you a pint...
|
|
|
Post by JHam on Nov 13, 2014 16:38:17 GMT
Wow that's great RLC! I think you get the bargain basement buy trophy Seriously though, up 30% with the main catalyst still at least 2 months out bodes well in my opinion. Ya I got lucky with my purchase price. I think you had mentioned you opened a small position ~$4.70. Shortly after, I did a little digging into the company, liked what I saw and decided to buy. It was trading at ~$4.50 I believe and I got my first purchase in at $4.60. A few days later, it continued trading down slightly, and I managed to grab a larger chunk at $4.45. Between this one and ONCS, I'd say I owe you a pint... You owe me nothing but continued warm friendship on this board And you don't even owe me that, lol. I just hope we are all able to lock in nice sizapeable profits and don't get too greedy.
|
|
|
Post by JHam on Nov 13, 2014 16:49:02 GMT
Well here is the big news of the day: www.prnewswire.com/news-releases/nuvo-research-reacquires-pennsaid-2-rights-to-south-america-central-america-south-africa-and-israel-282543391.htmlNuvo Research® reacquires Pennsaid® 2% rights to South America, Central America, South Africa and Israel MISSISSAUGA, ON, Nov. 13, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced that it has reacquired Pennsaid 2% marketing rights to South America, Central America, South Africa and Israel from Paladin Labs Inc. for non-cash consideration. The Company now owns all ex-U.S. Pennsaid 2% rights and will be seeking a partner or partners to market Pennsaid 2% internationally except in Canada, Russia and Greece where it already has marketing partnerships in place. "We are pleased to have reacquired these rights for key promising territories," said Dan Chicoine, Nuvo's Chairman and Co-CEO. "Outlicensing Pennsaid 2% for these and other territories to a capable partner or partners is an important part of our plan to make Pennsaid 2% a global brand."
|
|